SEC 13F Intelligence

Managers / Q3 2021 · view latest →

Krensavage Asset Management, LLC

CIK 0001609251 · 610 FIFTH AVENUE, SUITE 301, NEW YORK, NY, 10020 · 212-888-1582

Reported Value
$319M
Q3 2021
Positions
13
Filings on Record
32
2019–present window
Filed
Nov 16, 2021
original filing

Summary

Krensavage Asset Management, LLC reported $319M in U.S.-listed holdings across 13 positions for Q3 2021.

Its largest position, ENTA, represents 16.7% of the portfolio.

Compared with Q2 2021, the fund opened 1 new position and exited 1.

Portfolio Metrics

Turnover
+5.6%
vs prior filed quarter
Top-10 Concentration
+97.6%
share of reported value
Largest Position
+16.7%
Enanta Pharmaceuticals
New / Exited
1 / 1
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $370MQ1 ’19Q2 ’19: $308MQ3 ’19: $260MQ4 ’19: $293MQ1 ’20: $311MQ1 ’20Q2 ’20: $368MQ3 ’20: $314MQ4 ’20: $342MQ1 ’21: $289MQ1 ’21Q2 ’21: $295MQ3 ’21: $319MQ4 ’21: $288MQ1 ’22: $290MQ1 ’22Q2 ’22: $302MQ3 ’22: $314MQ4 ’22: $324MQ1 ’23: $329MQ1 ’23Q2 ’23: $316MQ3 ’23: $272MQ4 ’23: $282MQ1 ’24: $226MQ1 ’24Q2 ’24: $218MQ3 ’24: $178MQ4 ’24: $169MQ1 ’25: $181MQ1 ’25Q2 ’25: $189MQ3 ’25: $235MQ4 ’25: $283MQ1 ’26: $256MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 89.1%Other: 10.9%
  • Common Stock · 89.1% · $284M
  • Other · 10.9% · $35M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
EXELEXELIXIS INCNEW+1.00M1.00M+$21M$21M
ANABANAPTYSBIO INCSOLD OUT−10.9K0−$282,000$0
EGRXEAGLE PHARMACEUTICALS INCADDED+37.0K107.8K+$3M$6M
ALKSALKERMES PLCTRIMMED−246.9K1.44M+$3M$44M
REGNREGENERON PHARMACEUTICALSTRIMMED−9.0K73.1K−$2M$44M
BIIBBIOGEN INCADDED+5.7K103.2K−$5M$29M
UTHRUNITED THERAPEUTICS CORPTRIMMED−12.4K207.3K−$1M$38M
TVTXTRAVERE THERAPEUTICS INCHELD−2.8K137.2K+$1M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2021

13 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ENTAENANTA PHARMACEUTICALS INChistory →COM16.69%$53M936.8K
2ALKSALKERMES PLChistory →COM13.95%$44M1.44M
3REGNREGENERON PHARMACEUTICALShistory →COM13.89%$44M73.1K
4UTHRUNITED THERAPEUTICS CORPhistory →COM12.00%$38M207.3K
5TARO PHARMACEUTICAL INDUSCOM10.89%$35M545.6K
6MCKMCKESSON CORPhistory →COM10.29%$33M164.6K
7BIIBBIOGEN INChistory →COM9.16%$29M103.2K
8EXELEXELIXIS INChistory →COM6.63%$21M1.00M
9SURGALIGN HOLDINGS INCCOM2.17%$7M6.33M
10EGRXEAGLE PHARMACEUTICALS INChistory →COM1.89%$6M107.8K
11INVACARE CORPCOM1.33%$4M891.3K
12TVTXTRAVERE THERAPEUTICS INChistory →COM1.04%$3M137.2K
13NEXTCURE INCCOM0.07%$208,00030.9K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$256M20May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$283M18Feb 18, 202613F-HRchanges · EDGAR ↗
Q3 2025$235M17Nov 17, 202513F-HRchanges · EDGAR ↗
Q2 2025$189M15Aug 15, 202513F-HRchanges · EDGAR ↗
Q1 2025$181M14May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$169M12Feb 18, 2025RESTATEMENTchanges · EDGAR ↗
Q3 2024$178M13Nov 15, 202413F-HRchanges · EDGAR ↗
Q2 2024$218M13Aug 15, 202413F-HRchanges · EDGAR ↗
Q1 2024$226M12May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$282M12Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$272M12Nov 15, 202313F-HRchanges · EDGAR ↗
Q2 2023$316M12Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$329M12May 16, 202313F-HRchanges · EDGAR ↗
Q4 2022$324M12Feb 15, 202313F-HRchanges · EDGAR ↗
Q3 2022$314M14Nov 15, 202213F-HRchanges · EDGAR ↗
Q2 2022$302M14Aug 16, 202213F-HRchanges · EDGAR ↗
Q1 2022$290M13May 17, 202213F-HRchanges · EDGAR ↗
Q4 2021$288M10Feb 15, 202213F-HRchanges · EDGAR ↗
Q3 2021$319M13Nov 16, 202113F-HRchanges · EDGAR ↗
Q2 2021$295M13Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$289M12May 18, 202113F-HRchanges · EDGAR ↗
Q4 2020$342M12Feb 17, 202113F-HRchanges · EDGAR ↗
Q3 2020$314M11Dec 8, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$368M11Aug 20, 2020RESTATEMENTchanges · EDGAR ↗
Q1 2020$311M13May 18, 202013F-HRchanges · EDGAR ↗
Q4 2019$293M12Feb 18, 202013F-HRchanges · EDGAR ↗
Q3 2019$260M10Nov 15, 201913F-HRchanges · EDGAR ↗
Q2 2019$308M10Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$370M12May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.